Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, Dou X, Duan Z, Fan J, Gao Y, Han T, Han Y, Hu P, Huang Y, Huang Y, Jia J, Jiang J, Jiang Y, Li J, Li J, Li R, Li S, Li W, Li Y, Lin S, Liu J, Liu S, Lu L, Lu Q, Luo X, Ma X, Rao H, Ren H, Ren W, Shang J, Shi L, Su M, Wang B, Wang R, Wei L, Wen Z, Wu B, Wu J, Xin S, Xing H, Xu J, Yan M, Yang J, Yang J, Yang L, Yang Y, Yu Y, Zhang L, Zhang L, Zhang X, Zhang Y, Zhang Y, Zhao J, Zhao S, Zheng H, Zhou Y, Zhou Y, Zhuang H, Zuo W, Xu X, Qiao L. Nan Y, et al. Among authors: dou x. J Hepatol. 2021 Aug;75(2):454-461. doi: 10.1016/j.jhep.2021.05.003. Epub 2021 May 19. J Hepatol. 2021. PMID: 34019941
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection.
Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Rao H, et al. Among authors: dou x. J Gastroenterol Hepatol. 2014 Mar;29(3):545-53. doi: 10.1111/jgh.12398. J Gastroenterol Hepatol. 2014. PMID: 24090188 Free PMC article.
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. Sun J, et al. Among authors: dou x. Hepatology. 2014 Apr;59(4):1283-92. doi: 10.1002/hep.26885. Epub 2014 Feb 28. Hepatology. 2014. PMID: 24382690 Clinical Trial.
Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.
Liang X, Cheng J, Sun Y, Chen X, Li T, Wang H, Jiang J, Chen X, Long H, Tang H, Yu Y, Sheng J, Chen S, Niu J, Ren H, Shi J, Dou X, Wan M, Jiang J, Xie Q, Shi G, Ning Q, Chen C, Tan D, Ma H, Sun J, Jia J, Zhuang H, Hou J. Liang X, et al. Among authors: dou x. J Gastroenterol Hepatol. 2015 Apr;30(4):748-55. doi: 10.1111/jgh.12835. J Gastroenterol Hepatol. 2015. PMID: 25352300 Clinical Trial.
[High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study].
Chen X, Shang J, Yang R, Xie Q, Gao Z, Xu X, Dou X, Gong G, Chen G, Li J, Chen H, Zhang D, Feng Y, Niu J, Hou J, You H, Wu Y, Zhao P, Rao H, Wei L. Chen X, et al. Among authors: dou x. Zhonghua Gan Zang Bing Za Zhi. 2015 Jun;23(6):412-7. doi: 10.3760/cma.j.issn.1007-3418.2015.06.004. Zhonghua Gan Zang Bing Za Zhi. 2015. PMID: 26236925 Clinical Trial. Chinese.
[The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients].
Rao H, Yang R, Shang J, Xu X, Chen X, Dou X, Feng Y, Gao Z, Xie Q, Li J, You H, Chen G, Niu J, Gong G, Hou J, Chen H, Zhang D, Wei L. Rao H, et al. Among authors: dou x. Zhonghua Nei Ke Za Zhi. 2015 Aug;54(8):699-704. Zhonghua Nei Ke Za Zhi. 2015. PMID: 26674626 Clinical Trial. Chinese.
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
Chen GF, Wei L, Chen J, Duan ZP, Dou XG, Xie Q, Zhang WH, Lu LG, Fan JG, Cheng J, Wang GQ, Ren H, Wang JP, Yang XX, Jia ZS, Fu QC, Wang XJ, Shang J, Zhang YX, Han Y, Du N, Shao Q, Ji D, Li F, Li B, Liu JL, Niu XX, Wang C, Wu V, Wong A, Wang YD, Hou JL, Jia JD, Zhuang H, Lau G. Chen GF, et al. PLoS One. 2016 Jun 8;11(6):e0155934. doi: 10.1371/journal.pone.0155934. eCollection 2016. PLoS One. 2016. PMID: 27276081 Free PMC article.
1,544 results